A payer looking at a new medicine is really asking two things. Is it worth it? And can we afford it? Cost effectiveness answers the first. Budget impact answers the second. They use some of the same inputs, but they are different questions with different audiences.
Cost effectiveness: is it worth it?
Cost effectiveness compares the new medicine with current care. It asks how much extra it costs to gain one extra unit of health, often a quality-adjusted life year. The result is usually expressed as a ratio: additional cost divided by additional benefit.
It takes a long view, often the patient's lifetime, because the benefits of a treatment may continue for years. It does not care how many patients there are. A medicine for fifty patients and a medicine for fifty thousand can have the same ratio.
Budget impact: can we afford it?
Budget impact asks what happens to a specific payer's spending if the medicine is adopted. It looks at the eligible population, how quickly uptake grows, what the medicine displaces, and what other costs rise or fall. It usually covers three to five years, because that is the horizon budgets are planned on.
Here, the number of patients is everything.
Side by side
| Cost effectiveness | Budget impact | |
|---|---|---|
| Question | Is the extra benefit worth the extra cost? | What will this cost our budget? |
| Output | A ratio, such as cost per QALY gained | Total spending change per year |
| Time horizon | Long, often lifetime | Short, usually three to five years |
| Population size | Largely irrelevant | Central |
| Main audience | HTA and clinical committees | Budget holders and finance |
Why the distinction matters
A medicine can be highly cost effective and still unaffordable. A treatment that cures a common disease may offer excellent value per patient while costing more in its first year than the payer can find. The reverse also happens: a cheap medicine for a small group may have a modest budget impact but a poor ratio.
This is why the conversation with a payer needs both. If you argue value to someone whose problem is affordability, you are answering a question they did not ask. If you show a manageable budget to a committee that doubts the benefit, you have not addressed their concern.
Know which question the person in front of you is responsible for answering.
In many MENA systems, formal cost effectiveness thresholds are still evolving while budget pressure is immediate. That makes a credible, locally grounded budget impact analysis especially important, and it makes the epidemiology behind it the first thing a payer will test.